

Marie Beylot-Barry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/550406/publications.pdf>

Version: 2024-02-01

235
papers

9,983
citations

31976

53
h-index

48315

88
g-index

304
all docs

304
docs citations

304
times ranked

7370
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring <i>hTERT</i> promoter methylation in cutaneous T-cell lymphomas. <i>Molecular Oncology</i> , 2022, 16, 1931-1946.	4.6	12
2	Vismodegib efficacy in unresectable trichoblastic carcinoma: A multicenter study of 16 cases. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1365-1366.	1.2	3
3	From neglect to earlier diagnosis: a qualitative meta-synthesis of psycho-social factors associated with consultation delay in advanced basal cell carcinoma. <i>Psychology, Health and Medicine</i> , 2022, 27, 1793-1804.	2.4	2
4	Place de la radiothérapie dans le traitement des lymphomes cutanés. <i>Annales De Dermatologie Et De Vénéréologie</i> , FMC, 2022, , .	0.0	0
5	How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1202-1210.	1.3	1
6	CITY-PSO: Prescribing behaviour of French private-practice dermatologists in psoriasis management: An observational, multicentre, cross-sectional study. <i>Annales De Dermatologie Et De Vénéréologie</i> , 2022, , .	1.0	0
7	Telomeric Repeat-Containing RNA (TERRA): A Review of the Literature and First Assessment in Cutaneous T-Cell Lymphomas. <i>Genes</i> , 2022, 13, 539.	2.4	6
8	Integrative diagnosis of primary cutaneous large B-cell lymphomas supports the relevance of cell of origin profiling. <i>PLoS ONE</i> , 2022, 17, e0266978.	2.5	4
9	Attitudes, Barriers, Motivations to Sun Protection in Reunion Island's Schools: Qualitative Study. <i>Risk Management and Healthcare Policy</i> , 2022, Volume 15, 895-900.	2.5	3
10	Impact of Childhood Onset Psoriasis on Addictive Behaviours, Socioeconomic and Educational Data in Adulthood. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00733.	1.3	2
11	Mogamulizumab-induced granulomatous dermatitis of the scalp: a distinct entity associated with clinical response. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	5
12	Sweet-like syndrome and multiple COVID arm syndrome following COVID-19 vaccines: specific patterns in a series of 192 patients. <i>British Journal of Dermatology</i> , 2022, 187, 615-617.	1.5	6
13	The harmful effects of aesthetic care: Dealing with new kinds of exogenous acne. <i>Annales De Dermatologie Et De Vénéréologie</i> , 2022, , .	1.0	0
14	Primary intralymphatic histiocytosis: Case report and literature review. <i>Annales De Dermatologie Et De Vénéréologie</i> , 2022, , .	1.0	0
15	Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 3243-3252.e10.	0.7	6
16	Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*. <i>British Journal of Dermatology</i> , 2021, 184, 524-531.	1.5	18
17	Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 97-105.	0.4	18
18	Guidelines for the management of hidradenitis suppurativa: recommendations supported by the Centre of Evidence of the French Society of Dermatology. <i>British Journal of Dermatology</i> , 2021, 184, 963-965.	1.5	15

#	ARTICLE	IF	CITATIONS
19	Diagnosis and treatment of lymphomas in the era of epigenetics. <i>Blood Reviews</i> , 2021, 48, 100782.	5.7	7
20	Disseminated cutaneous granulomatosis as a manifestation of myelodysplastic syndrome. <i>International Journal of Dermatology</i> , 2021, 60, 628-630.	1.0	0
21	Acquired cutis laxa associated with neutrophilic urticarial dermatosis. <i>International Journal of Dermatology</i> , 2021, 60, 771-772.	1.0	3
22	Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry*. <i>British Journal of Dermatology</i> , 2021, 184, 1059-1067.	1.5	39
23	Xenograft and cell culture models of SÅ©zary syndrome reveal cell of origin diversity and subclonal heterogeneity. <i>Leukemia</i> , 2021, 35, 1696-1709.	7.2	16
24	Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas. <i>British Journal of Dermatology</i> , 2021, 184, 356-358.	1.5	1
25	Clinical factors predictive for histological aggressiveness of basal cell carcinoma: A prospective study of 2274 cases. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 23-27.	1.0	16
26	Baseline Characteristics of a National French E-Cohort of Hidradenitis Suppurativa in ComPaRe and Comparison with Other Large Hidradenitis Suppurativa Cohorts. <i>Dermatology</i> , 2021, 237, 748-758.	2.1	4
27	Facilitators of and obstacles to consultation in patients with advanced basal cell carcinoma: a French pilot study. <i>Archives of Dermatological Research</i> , 2021, 313, 829-835.	1.9	2
28	Mycosis fungoÃde et lymphomes T Å©rythrodermiques. <i>Annales De Dermatologie Et De VÃ©nÃ©rologie</i> , FMC, 2021, 1, 40-47.	0.0	1
29	Lack of clinical relevance of blood clonality in primary cutaneous marginal zone B-cell lymphoma. <i>European Journal of Dermatology</i> , 2021, 31, 94-96.	0.6	3
30	Vindesine dexamethasone as a therapeutic option in elderly blastic plasmacytoid dendritic cell neoplasms: a monocentric experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-3.	1.3	2
31	NonÃ©acral skin manifestations during the COVIDÃ©19 epidemic: COVIDSKIN study by the French Society of Dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e539-e541.	2.4	3
32	Guidelines for the management of chronic spontaneous urticaria: recommendations supported by the Centre of Evidence of the French Society of Dermatology. <i>British Journal of Dermatology</i> , 2021, 185, 658-660.	1.5	8
33	Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1441-1451.	1.3	6
34	Lymph node and visceral progression without erythroderma or blood worsening in erythrodermic cutaneous TÃ©cell lymphoma: nine cases. <i>British Journal of Dermatology</i> , 2021, 185, 1061-1063.	1.5	2
35	Characteristics of patients with psoriasis with Psoriasis Area and Severity Index < 10 treated with biological agents: results from the French PsoBioTeq cohort. <i>British Journal of Dermatology</i> , 2021, 185, 1052-1054.	1.5	2
36	Clinicopathologic analysis of trichoblastoma and comparison with nodular basal cell carcinoma. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 177-182.	1.0	4

#	ARTICLE	IF	CITATIONS
37	Surgical treatment of rhinophyma: Retrospective monocentric study and literature review. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 172-176.	1.0	2
38	Characterization of advanced basal cell carcinoma patients progressing while receiving Hedgehog pathway inhibitors. <i>British Journal of Dermatology</i> , 2021, , .	1.5	0
39	Mogalizumab-induced granulomatous eruption of the scalp: a distinct entity associated with clinical response?. <i>European Journal of Cancer</i> , 2021, 156, S49-S50.	2.8	0
40	Targeting Epigenetic Modifiers Can Reduce the Clonogenic Capacities of SÄ©zary Cells. <i>Frontiers in Oncology</i> , 2021, 11, 775253.	2.8	3
41	Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. <i>European Journal of Cancer</i> , 2021, 157, 474-484.	2.8	45
42	Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database. <i>ESMO Open</i> , 2021, 6, 100284.	4.5	7
43	Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Psoriasis Patients from the PsoBioTeq Cohort. <i>Acta Dermato-Venereologica</i> , 2021, , .	1.3	4
44	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Antiâ€‘PD-1 Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 1821-1829.	3.0	17
45	Accuracy of Store-and-Forward Teledermatology for the Diagnosis of Skin Cancer: The Nouvelle-Aquitaine Experience. <i>Iproceedings</i> , 2021, 6, e35404.	0.1	0
46	A Multicentre Randomised Controlled Study Evaluating the Effect of a Standardised Education Programme on Quality of Life, Disease Severity, and Disease Knowledge in Patients with Moderate-To-Severe Psoriasis: The EDUPSO Study. <i>Dermatology</i> , 2021, , 1-10.	2.1	3
47	Characteristics associated with significantly worse quality of life in mycosis fungoides/SÄ©zary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index () Tj ETQq1 1 0.784314 rgBT1@verlock710 Tf 503		
48	Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOITEQ. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 293-300.	2.4	36
49	Management of granulomatous foreign body reaction to fillers with methotrexate. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 817-820.	2.4	17
50	Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroidâ€‘sparing effect. <i>British Journal of Dermatology</i> , 2020, 182, 1111-1119.	1.5	55
51	Challenges in Assessing MYC Rearrangement in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type. <i>American Journal of Surgical Pathology</i> , 2020, 44, 424-427.	3.7	3
52	Negative tests for SARSâ€‘CoVâ€‘2 infection do not rule out its responsibility for chilblains: reply from the authors. <i>British Journal of Dermatology</i> , 2020, 183, 1151-1152.	1.5	0
53	Impact of the French guidelines on the prescribing habits of systemic treatments for moderateâ€‘toâ€‘severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e747-e748.	2.4	4
54	Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders. <i>American Journal of Surgical Pathology</i> , 2020, 44, 862-872.	3.7	36

#	ARTICLE	IF	CITATIONS
55	Low Prevalence of GSC Gene Mutations in a Large Cohort of Predominantly Caucasian Patients with Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2085-2088.e14.	0.7	47
56	Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e686-e689.	2.4	61
57	Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing*. <i>British Journal of Dermatology</i> , 2020, 183, 866-874.	1.5	65
58	Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy. <i>JAMA Dermatology</i> , 2020, 156, 545.	4.1	40
59	HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma. <i>Blood</i> , 2020, 135, 1058-1061.	1.4	29
60	Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema. <i>Blood</i> , 2020, 135, 1101-1110.	1.4	15
61	Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2334-2342.e8.	0.7	28
62	Severe hypercalcemia complicating granulomatous slack skin disease: an exceptional case. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e354-e356.	2.4	3
63	Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1984-1992.	2.4	29
64	Cutaneous lymphomas appearing during treatment with biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database. <i>British Journal of Dermatology</i> , 2019, 181, 616-618.	1.5	15
65	Pyoderma gangrenosum misdiagnosed as necrotising fasciitis or a real association between the two?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e305-e306.	2.4	6
66	Primary cutaneous large B-cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases. <i>Histopathology</i> , 2019, 74, 1067-1080.	2.9	28
67	Clinical presentation, therapeutic approach and outcome of primary cutaneous marginal zone B-cell lymphoma presenting as AL amyloidoma of the skin. <i>British Journal of Dermatology</i> , 2019, 181, 607-609.	1.5	7
68	GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. <i>British Journal of Dermatology</i> , 2019, 180, 647-656.	1.5	51
69	Three cases of bacterial osteomyelitis associated with hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2019, 180, 1537-1538.	1.5	4
70	Treatment of mycosis fungoides and S�azary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma. <i>British Journal of Dermatology</i> , 2019, 180, 423-424.	1.5	5
71	The PROCLIFI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. <i>British Journal of Dermatology</i> , 2019, 181, 350-357.	1.5	127
72	T-cell papulosis associated with B-cell malignancy: a distinctive clinicopathologic entity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1469-1475.	2.4	19

#	ARTICLE	IF	CITATIONS
73	A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1982-1989.	0.7	27
74	Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas. <i>Modern Pathology</i> , 2018, 31, 1332-1342.	5.5	31
75	Paradoxical psoriasiform reactions to antitumour necrosis factor drugs in hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2018, 178, 281-283.	1.5	13
76	Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 437-440.	2.4	30
77	PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. <i>American Journal of Surgical Pathology</i> , 2018, 42, 326-334.	3.7	38
78	« Malignant » Rosacea as a sign of systemic marginal zone lymphoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e71-e72.	2.4	0
79	Trends in hospitalization rates for psoriasis flares since the introduction of biologics: a time series in France between 2005 and 2015. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1920-1929.	2.4	10
80	Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study. <i>British Journal of Dermatology</i> , 2018, 179, 1322-1328.	1.5	31
81	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1192-1204.	10.7	398
82	Predictors of long-term drug survival for infliximab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 96-101.	2.4	15
83	Intravenous cidofovir for diffuse genital warts in the setting of multifactorial immunosuppression. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e162-e163.	2.4	3
84	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1984-1994.	0.7	93
85	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet</i> , The, 2017, 390, 555-566.	13.7	444
86	Central nervous system involvement of primary cutaneous diffuse large B-cell lymphoma, leg type: 13 cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e498-e501.	2.4	11
87	Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2046-2054.	2.4	30
88	First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. <i>Lancet</i> , The, 2017, 389, 2031-2040.	13.7	438
89	A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. <i>European Journal of Dermatology</i> , 2017, 27, 286-294.	0.6	16
90	Expression of TFH Markers and Detection of RHOA p.G17V and IDH2 p.R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1581-1592.	3.7	21

#	ARTICLE	IF	CITATIONS
91	Molecular analysis of immunoglobulin variable genes supports a germinal center experienced normal counterpart in primary cutaneous diffuse large B-cell lymphoma, leg-type. <i>Journal of Dermatological Science</i> , 2017, 88, 238-246.	1.9	11
92	Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients. <i>European Journal of Dermatology</i> , 2017, 27, 271-274.	0.6	11
93	Pyoderma gangrenosum with extensive pulmonary involvement. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e214-e216.	2.4	8
94	Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF-alpha Inhibitors. <i>Acta Dermato-Venereologica</i> , 2017, 97, 731-734.	1.3	13
95	Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy. <i>Acta Dermato-Venereologica</i> , 2017, 97, 358-364.	1.3	57
96	TP53 alterations in primary and secondary SÅ©zary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma. <i>PLoS ONE</i> , 2017, 12, e0173171.	2.5	13
97	Risk factors, clinical variants and therapeutic outcome of retronychia: a retrospective study of 18 patients. <i>European Journal of Dermatology</i> , 2016, 26, 377-381.	0.6	25
98	AmÃ©lioration durable des manifestations cutanÃ©es et de la fonction physique avec le sÃ©cukinumab versus lâ€™ustÃ©kinumab chez les patients atteints de psoriasis modÃ©rÃ© Ã sÃ©vÃ©re et de rhumatisme psoriasique concomitant: rÃ©sultats de lâ€™Ã©tude CLEAR Ã 1 an. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016, 83, A174.	0.0	0
99	Intrahepatic Xenograft of Cutaneous T-Cell Lymphoma Cell Lines. <i>American Journal of Pathology</i> , 2016, 186, 1775-1785.	3.8	11
100	MYD88 Somatic Mutation Is a Diagnostic Criterion in Primary Cutaneous Large B-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1741-1744.	0.7	46
101	Sirolimus-related anal ulceration in a female patient after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 132-133.	2.4	2
102	Systemic sarcoidosis revealed by sarcoidal granulomas on tattoo. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1045-1046.	2.4	5
103	Phase multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/SÅ©zary syndrome. <i>British Journal of Dermatology</i> , 2016, 175, 80-88.	1.5	56
104	Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug development. <i>British Journal of Dermatology</i> , 2016, 175, 636-638.	1.5	26
105	Expression of SÅ©zary Biomarkers in the Blood of Patients with Erythrodermic Mycosis Fungoides. <i>Journal of Investigative Dermatology</i> , 2016, 136, 317-320.	0.7	16
106	Complete Remission of Squamous Cell Carcinoma After Treatment With Panitumumab in a Patient With Cetuximab-Induced Anaphylaxis. <i>JAMA Dermatology</i> , 2016, 152, 343.	4.1	11
107	Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis. <i>Oncologist</i> , 2016, 21, 76-83.	3.7	42
108	Molecular alterations and tumor suppressive function of the <i>DUSP22 (Dual Specificity) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Td (f	1.8	41

#	ARTICLE	IF	CITATIONS
109	Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases. <i>British Journal of Dermatology</i> , 2015, 172, 1547-1554.	1.5	58
110	Folliculotropic Tâ€cell infiltrates associated with Bâ€cell chronic lymphocytic leukaemia or <sc>MALT</sc> lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 77-85.	2.4	11
111	SÃ©zary syndrome without erythroderma. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 1003-1009.e1.	1.2	19
112	Defining and recognising locally advanced basal cell carcinoma. <i>European Journal of Dermatology</i> , 2015, 25, 586-594.	0.6	24
113	A Phase <sc>II</sc> trial of Belinostat (<sc>PXD</sc>101) in patients with relapsed or refractory peripheral or cutaneous Tâ€cell lymphoma. <i>British Journal of Haematology</i> , 2015, 168, 811-819.	2.5	172
114	Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 242-248.	1.2	222
115	Efficacy of Vinblastine in Primary Cutaneous Anaplastic Large Cell Lymphoma. <i>JAMA Dermatology</i> , 2015, 151, 1030.	4.1	8
116	Diagnostic and Prognostic Value of <i>BCL2</i> Rearrangement in 53 Patients With Follicular Lymphoma Presenting as Primary Skin Lesions. <i>American Journal of Clinical Pathology</i> , 2015, 143, 362-373.	0.7	38
117	<sc>BRAF</sc> inhibitorsâ€induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 392-393.	2.4	12
118	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and SÃ©zary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. <i>Journal of Clinical Oncology</i> , 2015, 33, 3766-3773.	1.6	328
119	PLCG1 Gene Mutations Are Uncommon in Cutaneous T-Cell Lymphomas. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2334-2337.	0.7	16
120	Acral Acquired Cutis Laxa Associated with IgA Multiple Myeloma, Joint Hyperlaxity and Urticarial Neutrophilic Dermatitis. <i>Acta Dermato-Venereologica</i> , 2014, 94, 743-744.	1.3	8
121	Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2014, 27, 402-411.	5.5	78
122	Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. <i>Haematologica</i> , 2014, 99, 527-534.	3.5	73
123	Treatment (biotherapy excluded) of psoriatic arthritis: an appraisal of methodological quality of international guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 33-39.	2.4	6
124	Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 17-26.	2.4	72
125	Evidenceâ€based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 3-12.	2.4	25
126	Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France. <i>JAMA Dermatology</i> , 2014, 150, 535.	4.1	80

#	ARTICLE	IF	CITATIONS
127	High Frequency and Clinical Prognostic Value of MYD88 L265P Mutation in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type. <i>JAMA Dermatology</i> , 2014, 150, 1173.	4.1	110
128	Primary cutaneous follicle center lymphoma with Hodgkin and Reedâ€Sternbergâ€like cells: a new histopathologic variant. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 797-801.	1.3	18
129	Symptoms dermatologists should look for in daily practice to improve detection of psoriatic arthritis in psoriasis patients: an expert group consensus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 27-32.	2.4	24
130	Treatment for palmoplantar pustular psoriasis: systematic literature review, evidenceâ€based recommendations and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 13-16.	2.4	57
131	Observational case series on a group of psoriasis patients who failed to respond to any TNF blockers. <i>Journal of Dermatological Treatment</i> , 2014, 25, 75-77.	2.2	8
132	Telomerase functions beyond telomere maintenance in primary cutaneous T-cell lymphoma. <i>Blood</i> , 2014, 123, 1850-1859.	1.4	24
133	Lymphomatoid papulosis type D: an aggressive histology for an indolent disease. <i>British Journal of Dermatology</i> , 2013, 169, 1157-1159.	1.5	20
134	Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. <i>British Journal of Dermatology</i> , 2013, 169, 579-586.	1.5	141
135	MÃrgenes de resecciÃn oncolÃgica en cirugÃa dermatolÃgica. <i>EMC - DermatologÃa</i> , 2013, 47, 1-9.	0.1	0
136	CD20 Antigen May Be Expressed by Reactive or Lymphomatous Cells of Transformed Mycosis Fungoides. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1845-1854.	3.7	37
137	Recommandations pour le traitement des lymphomes T cutanÃs. , 2013, , 259-268.		0
138	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. <i>Haematologica</i> , 2013, 98, 1748-1752.	3.5	50
139	LymphoprolifÃrations cutanÃes CD30+: lymphome cutanÃ primitif Ã grandes cellules T CD30+ et papulose lymphomatoÃde. , 2013, , 95-110.		0
140	Lymphomes cutanÃs secondaires. , 2013, , 205-223.		1
141	MYD88 Somatic Mutation Is a Genetic Feature of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2118-2120.	0.7	85
142	Efficacy and Safety of Tumor Necrosis Factor Inhibitors in Acute Generalized Pustular Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 1423.	1.4	42
143	Primary Cutaneous Follicular Helper T-cell Lymphoma. <i>Archives of Dermatology</i> , 2012, 148, 832-9.	1.4	74
144	Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study. <i>Annals of Oncology</i> , 2012, 23, 1074-1080.	1.2	156

#	ARTICLE	IF	CITATIONS
145	Specific Skin Lesions in Chronic Myelomonocytic Leukemia. American Journal of Surgical Pathology, 2012, 36, 1302-1316.	3.7	97
146	Acquired Dermal Melanocytosis of the Back in a Caucasian Woman. American Journal of Dermatopathology, 2012, 34, 562-563.	0.6	9
147	Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm. Supportive Care in Cancer, 2012, 20, 1395-1404.	2.2	29
148	Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. British Journal of Dermatology, 2012, 167, 417-423.	1.5	42
149	Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. British Journal of Dermatology, 2012, 167, 643-648.	1.5	31
150	About some red faces. Annales De Dermatologie Et De Venereologie, 2011, 138, S201-S206.	1.0	2
151	Lymphoma-associated hemophagocytic syndrome (LAHS) in advanced-stage mycosis fungoides/S�azary syndrome cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2011, 65, 404-410.	1.2	16
152	Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure. British Journal of Dermatology, 2011, 165, 985-989.	1.5	63
153	Histologic and Immunohistologic Characterization of Skin Localization of Myeloid Disorders. American Journal of Clinical Pathology, 2011, 135, 278-290.	0.7	83
154	Bone involvement in two cases of thoracic primary cutaneous diffuse large B-cell lymphoma, leg type. European Journal of Dermatology, 2011, 21, 744-749.	0.6	3
155	Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?. British Journal of Dermatology, 2010, 162, 74-79.	1.5	136
156	IRF4 Gene Rearrangements Define a Subgroup of CD30-Positive Cutaneous T-Cell Lymphoma: A Study of 54 Cases. Journal of Investigative Dermatology, 2010, 130, 816-825.	0.7	114
157	IRF4 Expression without IRF4 Rearrangement Is a General Feature of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Journal of Investigative Dermatology, 2010, 130, 1470-1472.	0.7	10
158	Genome-Wide Analysis of Cutaneous T-Cell Lymphomas Identifies Three Clinically Relevant Classes. Journal of Investigative Dermatology, 2010, 130, 1707-1718.	0.7	100
159	Clinicopathological Study of 13 Cases of Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa. Dermatology, 2010, 220, 147-153.	2.1	99
160	Disseminated Cutaneous Lymphoid Hyperplasia of 12 Years�™ Duration Triggered by Vaccination. Dermatology, 2010, 220, 176-179.	2.1	20
161	CDKN2A��CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Modern Pathology, 2010, 23, 547-558.	5.5	80
162	Treatment of Cutaneous B-Cell Lymphoma, Leg Type, With Age-Adapted Combinations of Chemotherapies and Rituximab. Archives of Dermatology, 2009, 145, 329-30.	1.4	37

#	ARTICLE	IF	CITATIONS
163	Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases. <i>British Journal of Dermatology</i> , 2009, 161, 660-663.	1.5	56
164	Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. <i>Blood</i> , 2009, 113, 2746-2754.	1.4	76
165	Lymphomes T cutanÃ©s (hors mycosis fungoÃ©de et syndrome de SÃ©zary). , 2009, , 25-35.		0
166	Inactivation of p16 INK4a /CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 452, 607-620.	2.8	38
167	Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis. <i>Arthritis and Rheumatism</i> , 2008, 58, 1796-1802.	6.7	33
168	Primary Cutaneous T-Cell Lymphomas Do not Show Specific NAV3 Gene Deletion or Translocation. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2458-2466.	0.7	24
169	Oral erosive lichen planus and Good's syndrome: just a coincidence or a direct link between the two diseases?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 506-507.	2.4	13
170	Aggressive intermediate cell histiocytosis successfully treated by 2â€chlorodeoxyadenosine. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 1153-1156.	2.4	3
171	Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or SÃ©zary Syndrome. <i>Archives of Dermatology</i> , 2008, 144, 727-33.	1.4	88
172	Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. <i>Archives of Dermatology</i> , 2007, 143, 1144-50.	1.4	218
173	Cas nÂ° 4. <i>Annales De Pathologie</i> , 2007, 27, 295-297.	0.1	0
174	Cas nÂ° 2. <i>Annales De Pathologie</i> , 2007, 27, 290-292.	0.1	0
175	Common chromosomal abnormalities in mycosis fungoides transformation. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 828-838.	2.8	44
176	Necrotic livedo after vertebroplasty. <i>British Journal of Dermatology</i> , 2007, 156, 382-383.	1.5	8
177	Pityriasis rubra pilaris and hypothyroidism. Efficacy of thyroid hormone replacement therapy in skin recovery. <i>British Journal of Dermatology</i> , 2007, 156, 606-607.	1.5	18
178	Erythema annulare centrifugum revealing chronic lymphocytic leukaemia. <i>British Journal of Dermatology</i> , 2007, 157, 1045-1047.	1.5	15
179	The hand of the wine grower: hypothenar hammer syndrome. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 22, 070612045632002-???.	2.4	3
180	A suggested protocol for obtaining high-quality skin metaphases from primary cutaneous T-cell lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 2006, 167, 89-91.	1.0	9

#	ARTICLE	IF	CITATIONS
181	Treatment of Early-Stage Mycosis Fungoides With Twice-Weekly Applications of Mechlorethamine and Topical Corticosteroids. <i>Archives of Dermatology</i> , 2005, 141, 1117.	1.4	51
182	Is bone marrow biopsy necessary in patients with mycosis fungoides and Sezary syndrome? A histological and molecular study at diagnosis and during follow-up. <i>British Journal of Dermatology</i> , 2005, 152, 1378-1379.	1.5	10
183	Large cell transformation of mycosis fungoides: tetraploidization within skin tumor large cells. <i>Cancer Genetics and Cytogenetics</i> , 2005, 163, 1-6.	1.0	21
184	Blastic NK-Cell Lymphomas (Agranular CD4+CD56+ Hematodermic Neoplasms). <i>American Journal of Clinical Pathology</i> , 2005, 123, 662-675.	0.7	266
185	Définition, classification, diagnostic clinique et histologique des lymphomes T cutanés. <i>Annales De Dermatologie Et De Venereologie</i> , 2005, 132, 5-10.	1.0	1
186	Serial chest CT findings in interstitial lung disease associated with polymyositis/dermatomyositis. <i>European Journal of Radiology</i> , 2004, 49, 235-244.	2.6	74
187	Neoplastic Cells Do Not Carry bcl2-JH Rearrangements Detected in a Subset of Primary Cutaneous Follicle Center B-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2004, 28, 748-755.	3.7	51
188	Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. <i>Blood</i> , 2004, 103, 3662-3668.	1.4	139
189	Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn's disease. <i>British Journal of Dermatology</i> , 2003, 149, 181-184.	1.5	56
190	Chromosomal imbalances: a hallmark of tumour relapse in primary cutaneous CD30+ T-cell lymphoma. <i>Journal of Pathology</i> , 2003, 201, 421-429.	4.5	22
191	Histiocytosis de células de Langerhans y sin células de Langerhans. <i>EMC - Dermatología</i> , 2003, 37, 1-11.	0.1	0
192	Bone Marrow Histopathologic and Molecular Staging in Epidermotropic T-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2003, 119, 414-423.	0.7	51
193	Relevance of Vertical Growth Pattern in Thin Level II Cutaneous Superficial Spreading Melanomas. <i>American Journal of Surgical Pathology</i> , 2003, 27, 717-724.	3.7	42
194	Bone Marrow Histopathologic and Molecular Staging in Epidermotropic T-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2003, 119, 0-0.	0.7	0
195	Value of Interphase FISH for the Diagnosis of t(11;14)(q13;q32) on Skin Lesions of Mantle Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2002, 118, 832-841.	0.7	38
196	The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: A prospective study. <i>International Journal of Cancer</i> , 2002, 102, 34-38.	5.1	60
197	Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases. <i>British Journal of Dermatology</i> , 2002, 146, 320-324.	1.5	82
198	Mycosis fungoides mimicking granuloma annulare. <i>British Journal of Dermatology</i> , 2002, 146, 1102-1103.	1.5	24

#	ARTICLE	IF	CITATIONS
199	Sodium valproate-induced cutaneous pseudolymphoma followed by recurrence with carbamazepine. <i>British Journal of Dermatology</i> , 2001, 144, 1235-1238.	1.5	44
200	Red fingers syndrome: acrosyndrome related to vascular growth endothelial factor?. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 219-220.	1.3	8
201	Evidence that an Identical T Cell Clone in Skin and Peripheral Blood Lymphocytes is an Independent Prognostic Factor in Primary Cutaneous T Cell Lymphomas. <i>Journal of Investigative Dermatology</i> , 2001, 117, 920-926.	0.7	74
202	Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 619-626.	1.2	205
203	Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. <i>Blood</i> , 2000, 95, 2212-8.	1.4	215
204	Dermatophytic Granuloma Caused by <i>Microsporium canis</i> in a Heart-Lung Recipient. <i>Dermatology</i> , 1999, 198, 317-319.	2.1	25
205	A Prospective Study of Cutaneous Intolerance to Topical Mechlorethamine Therapy in Patients With Cutaneous T-Cell Lymphomas. <i>Archives of Dermatology</i> , 1999, 135, 1349-53.	1.4	45
206	Treatment of pityriasis rubra pilaris: a retrospective study of 14 patients. <i>Journal of Dermatological Treatment</i> , 1999, 10, 113-117.	2.2	13
207	Successful Treatment of Subcorneal Pustular Dermatitis (Sneddon-Wilkinson Disease) by Acitretin: Report of a Case. <i>Dermatology</i> , 1999, 199, 153-155.	2.1	59
208	Pseudoepitheliomatous hyperplasia in cutaneous T-cell lymphoma. A clinical, histopathological and immunohistochemical study with particular interest in epithelial growth factor expression. <i>British Journal of Dermatology</i> , 1999, 140, 421-426.	1.5	56
209	Meningeal involvement by a transformed mycosis fungoides following Hodgkin's disease. <i>British Journal of Dermatology</i> , 1999, 141, 909-913.	1.5	10
210	Melanoma and Tumor Thickness. <i>Archives of Dermatology</i> , 1999, 135, 269-74.	1.4	102
211	The Spectrum of Cutaneous Lymphomas in HIV Infection. <i>American Journal of Surgical Pathology</i> , 1999, 23, 1208.	3.7	92
212	Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the SÅzary syndrome. The French Study Group on Cutaneous Lymphomas. <i>Blood</i> , 1999, 93, 3637-42.	1.4	77
213	Pilotropic mycosis fungoides. <i>Journal of the American Academy of Dermatology</i> , 1998, 38, 501.	1.2	14
214	Lymphomatoid contact dermatitis caused by isopropyl-diphenylenediamine: Two cases. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 152-153.	2.9	28
215	Primary Cutaneous <i>Nocardia asteroides</i> Infection after Heart Transplantation. <i>Dermatology</i> , 1998, 196, 246-247.	2.1	35
216	Oral Contraceptives and Cyproterone Acetate in Female Acne Treatment. <i>Dermatology</i> , 1998, 196, 148-152.	2.1	31

#	ARTICLE	IF	CITATIONS
217	Characterization of t(2;5) Reciprocal Transcripts and Genomic Breakpoints in CD30+ Cutaneous Lymphoproliferations. <i>Blood</i> , 1998, 91, 4668-4676.	1.4	74
218	Lichen planus following hepatitis B vaccination. <i>British Journal of Dermatology</i> , 1998, 139, 350-350.	1.5	25
219	Cutaneous Sarcoidosis Successfully Treated With Low Doses of Thalidomide. <i>Archives of Dermatology</i> , 1998, 134, 1045-1046.	1.4	61
220	Urticaria and hepatitis C infection. <i>British Journal of Dermatology</i> , 1998, 138, 194-195.	1.5	11
221	Statistical Evaluation of Diagnostic and Prognostic Features of CD30+ Cutaneous Lymphoproliferative Disorders. <i>American Journal of Surgical Pathology</i> , 1998, 22, 1192-1202.	3.7	102
222	Characterization of t(2;5) Reciprocal Transcripts and Genomic Breakpoints in CD30+ Cutaneous Lymphoproliferations. <i>Blood</i> , 1998, 91, 4668-4676.	1.4	1
223	Cutaneous localization of chronic lymphocytic leukemia at the site of chickenpox. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 98-99.	1.2	20
224	Acute generalized exanthematous pustulosis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 1996, 15, 244-249.	1.6	132
225	CD30-Positive Cutaneous Large Cell Lymphomas: A Comparative Study of Clinicopathologic and Molecular Features of 16 Cases. <i>American Journal of Clinical Pathology</i> , 1996, 105, 440-450.	0.7	47
226	Gluteal Pigmentation after Intramuscular Iron Injections. <i>Dermatology</i> , 1996, 192, 187-188.	2.1	6
227	Histiocytic sarcoma that mimicks benign histiocytosis. <i>Journal of Cutaneous Pathology</i> , 1996, 23, 275-283.	1.3	9
228	Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. <i>American Journal of Pathology</i> , 1996, 149, 483-92.	3.8	46
229	Contribution of histopathologic and molecular analyses to the diagnosis of cutaneous B-cell infiltrates. <i>Modern Pathology</i> , 1996, 9, 1147-55.	5.5	18
230	Ki-1-Positive Large-Cell Cutaneous Lymphoma Mimicking a Stewart-Treves Angiosarcoma. <i>Dermatology</i> , 1995, 190, 77-82.	2.1	13
231	p53 Oncoprotein Expression in Cutaneous Lymphoproliferations. <i>Archives of Dermatology</i> , 1995, 131, 1019.	1.4	13
232	Drug-induced linear IgA bullous dermatosis. <i>Journal of the American Academy of Dermatology</i> , 1995, 32, 296.	1.2	32
233	p53 oncoprotein expression in cutaneous lymphoproliferations. <i>Archives of Dermatology</i> , 1995, 131, 1019-1024.	1.4	18
234	Herpes simplex virus type 2 ascending myeloradiculitis: MRI findings and rapid diagnosis by the polymerase chain method.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994, 57, 869-870.	1.9	34

#	ARTICLE	IF	CITATIONS
235	Human Immunodeficiency Virus Type 1 Replication Within Cystic Lymphoepithelial Lesion of the Salivary Gland. American Journal of Clinical Pathology, 1993, 100, 41-46.	0.7	56